Albany, NY -- (SBWIRE) -- 07/08/2019 -- Polycythemia Vera Market Insights, Epidemiology and Market Forecast-2028
1. Polycythemia Vera incidence is approximately 2.8 per 100,000 population of men and approximately 1.3 per 100,000 population of women.
2. Polycythemia Vera annual incidence is estimated at approximately 1/36,000-1/100,000.
3. Polycythemia Vera incidence ranged from 0.4 per 100 000 per year to 2.8 per 100 000 per year among the various European registries.
DelveInsight launched a new report on Polycythemia Vera Market Insights, Epidemiology and Market Forecast-2028
Key benefits
1. Polycythemia Vera market report covers a descriptive overview and comprehensive insight of the Polycythemia Vera epidemiology and Polycythemia Vera market in the 7 MM (the United States, EU5 (Germany, Spain, France, Italy, UK) & Japan.)
2. Polycythemia Vera market report provides insights on the current and emerging therapies.
3. Polycythemia Vera market report provides a global historical and forecasted market covering drug outreach in 7 MM.
4. Polycythemia Vera market report offers an edge that will help in developing business strategies by understanding trends shaping and driving the Polycythemia Vera market.
Request for sample pages
"Polycythemia Vera peak incidence is age 50-70 years. However, this condition occurs in persons of all age groups, including early adulthood and childhood, albeit rarely."
Polycythemia Vera therapeutic options are limited, and no cure is available. The goal of current therapies is to prevent the occurrence of thrombosis/vascular events and delayed transformation to MF or AML. The patients with lower risk are treated with regular phlebotomy, and low-dose aspirin might be recommended. For higher-risk patients the therapeutic approach of hydroxyurea, Interferon alpha and ruxolitinib are recommended.
The current market only offers a few approved therapies for Polycythemia Vera treatment. Therefore, the availability of the therapeutic options remains an unmet need. The pipeline scenario in this space presents limited competition, therefore the companies investing in research and development activities need to dig deeper. However, the launch of Polycythemia Vera upcoming therapies will also contribute to the overall growth of Polycythemia Vera market during the forecast period of 2019-2028.
The expected launch of Polycythemia Vera potential therapies in the market, during the forecast period (2019- 2028), shall create a positive impact on Polycythemia Vera market size in 7MM like:-
1. Idasanutlin
2. Pacritinib
And many others
Companies involved are:-
1. Roche
2. CTI Biopharma
And many others
Table of contents
1. Report Introduction
2. Polycythemia Vera Market Overview at a Glance
3. Polycythemia Vera Disease Background and Overview
4. Polycythemia Vera Epidemiology and Patient Population
5. Polycythemia Vera Country-Wise Epidemiology
5.1. United States
5.2. EU-5
5.2.1. Germany
5.2.2. France
5.2.3. Italy
5.2.4. Spain
5.2.5. United Kingdom
5.3. Japan
6. Polycythemia Vera Treatment & Medical Practices
7. Polycythemia Vera Emerging Therapies
7.1. Key Cross Competition
7.2. Idasanutlin (RG7388) – Hoffmann-La Roche
7.3. Pacritinib – CTI Biopharma
8. Polycythemia Vera Market Size
9. 7MM Polycythemia Vera Country-Wise Market Analysis
9.2. United States
9.3. Germany
9.4. France
9.5. United Kingdom
9.6. Spain
9.7. Italy
9.8. Japan
10. Polycythemia Vera Report Methodology
11. DelveInsight Capabilities
12. Disclaimer
13. About DelveInsight
About DelveInsight
DelveInsight is a leading Business Consultant, and Market Research Firm focused exclusively on life sciences. It supports pharma companies by providing end to end comprehensive solutions to improve their performance.
Contact us:
Shruti Thakur
info@delveinsight.com
+919650213330
SOURCE DelveInsight